Search tips
ECCMID 2023
Courses & Events
Guidelines
From the archive: ECCMID and more before 2010
Search Results
Sort by:
Filter 0
Sort by
Filter
Sort by
Relevance
Date descending
Date ascending
18 April 2023 - O1136
All-cause and attributable mortality in invasive candidiasis and/or Candidaemia with rezafungin and caspofungin treatment: outcomes from the ReSTORE trial
George Thompson, Oliver A Cornely, Alex Soriano, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F Das, Taylor Sandison, Peter G Pappas
16 April 2023 - P2048
Rezafungin and caspofungin treatment response in candidaemia/invasive candidiasis by baseline Candida species: analysis of pooled Phase 2 and Phase 3 results
George Thompson, Oliver A Cornely, Alex Soriano, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F Das, Taylor Sandison, Peter G Pappas
16 April 2023 - E0593
Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with Candidaemia and/or invasive candidiasis: integrated analysis of pooled Phase 2 and Phase 3 data
Oliver A Cornely, George R Thompson Rd, Alex Soriano, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F Das, Taylor Sandison, Peter G Pappas
16 April 2023 - P2063
Treatment outcomes in candidaemia and/or invasive candidiasis among patients receiving rezafungin or caspofungin while the fungal culture was still positive
Oliver A. Cornely, George R Thompson Rd, Alex Soriano, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F Das, Taylor Sandison, Peter G Pappas
16 April 2023 - P2061
Safety outcomes with rezafungin and caspofungin in the treatment of candidaemia and/or invasive candidiasis: phase 3 data from the ReSTORE trial
Alex Soriano, George R Thompson Rd, Oliver A Cornely, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F Das, Taylor Sandison, Peter G Pappas
2023
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Ignacio Martin-Loeches, Antoni Torres, Blin Nagavci, Stefano Aliberti, Massimo Antonelli, Matteo Bassetti, Lieuwe D Bos, James D Chalmers, Lennie Derde, Jan de Waele, Jose Garnacho-Montero, Marin Kollef, Carlos M Luna, Rosario Menendez, Michael S Niederman, Dmitry Ponomarev, Marcos I Restrepo, David Rigau, Marcus J Schultz, Emmanuel Weiss, Tobias Welte, Richard Wunderink
25 April 2022 - B0034
Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomised, double-blinded, multi-centre phase II and phase III trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
Alex Soriano, George R. Thompson, Oliver A Cornely, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M. Honore, Matteo Bassetti, John Pullman, Cecilia Dignani, Anita F. Das, Taylor Sandison, Peter G. Pappas
23 April 2022 - L0244
ReSTORE: efficacy and safety results of the phase III, noninferiority trial of rezafungin in the treatment of candidaemia and/or invasive candidiasis
George R. Thompson, Alex Soriano, Oliver A. Cornely, Bart-Jan Kullberg, Marin Kollef, Jose Vazquez, Patrick M. Honore, Matteo Bassetti, John Pullman, Methee Chayakulkeeree, Cecilia Dignani, Anita F. Das, Taylor Sandison, Peter G. Pappas
16 April 2019 - L0011
Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of the Monoclonal Antibody Combination ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Endotracheal Heavily Colo
Zoltan Magyarics, Karin Provost, Nimrod Adi, Tomasz Czarnik, Khatuna Japaridze, Nikoloz Kartsivadze, Mikhail Kirov, Ed Campanaro, Matthew Goodwin, Lori Muir, Marin Kollef, Chris Stevens
15 April 2019 - P1917
ASPECT-NP: a randomized, double-blind, phase III trial comparing efficacy and safety of ceftolozane/tazobactam versus meropenem in patients with ventilated nosocomial pneumonia (VNP)
Marin Kollef, Martin Nováček, Ülo Kivistik, Álvaro Réa-Neto, Nobuaki Shime, Ignacio Martin-Loeches, Jean-François Timsit, Richard G Wunderink, Christopher J. Bruno, Jennifer A. Huntington, Gina Lin, Brian Yu, Joan Butterton, Elizabeth G. Rhee
13 April 2019 - O0302
Clinical and microbiologic outcomes by causative pathogen in the ASPECT-NP randomised, controlled, phase III trial evaluating ceftolozane /tazobactam for treatment of ventilator-associated pneumonia
Ignacio Martin-Loeches, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Jean-François Timsit, Nobuaki Shime, Richard G Wunderink, Marin Kollef, Christopher J. Bruno, Jennifer A. Huntington, Gina Lin, Brian Yu, Joan Butterton, Elizabeth G. Rhee
24 April 2017 - OS0603
Phase 3, randomized, multicentre study of ceftazidime-avibactam versus meropenem in adults with nosocomial pneumonia including ventilator-associated pneumonia (REPROVE)
Stenmark Bianca, Antoni Torres, NanShan Zhong, Jan Pachl, Jean-François Timsit, Marin Kollef, Zhangjing Chen, Jie Song, Dianna Taylor, Peter Laud, Gregory Stone, Joseph Chow
25 April 2015 - EV0082
Pneumonia pathogen characterization is an independent determinant of hospital readmission
Marin Kollef, Kollef, Marin *; Andruska, Adam; Scott, Micek; Shindo, Yuichiro;
Loading ...
FAQ
To access content in the eLibrary you need to log in with your ESCMID member or user credentials. If you haven’t registered as an ESCMID member yet, then click here to do so – or use this link to register as a user.
The most recent event-related content is usually restricted to ESCMID members, while registered users get access one year after the event. However, there are events such as ECCMID where attendees get priority access, no matter if they are members or registered users. In these cases, we may offer non-attendees access after paying a fee.
You may search by event name, session title or number, topic title or number or author – or by any keyword. To get the most relevant results, enter the title or name in quotation marks, e.g. "Pre-ECCMID Day on Diagnostics" or "John Doe". If no quotation marks are used, then the exact result is shown first, followed by less exact results.
You may further narrow the number of search results for most terms by applying one or several filters, using the filter window on the start page. The Category and Media Type filters work for any content. In contrast, the Date from / to filter may not apply for Publications and Guidelines. In addition, the information text below a webcast or document offers the option of filtering search results by session title, author, event or category.
We defined four "hot topic" terms that you may search for by clicking the four tiles on the start page.
Linking two or more search terms by AND will show all results containing these search terms. For example, if you are looking for results that contain both the terms viral and hospital, then enter viral AND hospital.
Link two or more search terms by OR to get all results that contain at least one of these terms. For example, if you want to get results that contain either viral or infections or COVID, then enter viral OR infections OR COVID.
Place + in front of the term that you want to be included in your search result and place - in front of the term that you do not want to be included – without blanks in between in either case. For example, if you are aiming for search results that contain viral and infection but do not contain COVID, then enter +viral +infections -COVID.
A search term preceded by an exclamation point (no blanks in between) will lead to all content that does not contain the term, e.g. !COVID.
Deselect the ticked boxes in the filter dropdowns, click "Clear" on the calendars in the Date from / to filter – or refresh the website to remove all filters at once. Additionally, you may clear all applied filters by using the relevant buttons right above the search results.
No, as copyright protection limits the viewing of video presentations to web browsers, they cannot be downloaded.
No, due to our privacy policy we cannot disclose any contact details of persons involved.